Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 19Lymphoma, Mantle-Cell 9Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Waldenstrom Macroglobulinemia 2Recurrence 2Pancreatic Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Pyloric Stenosis, Hypertrophic 1Ovarian Neoplasms 1Neoplasm, Residual 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Hairy Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Glioblastoma 1DLBCL 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Anemia, Hemolytic, Autoimmune 1Advanced Haematological Malignancies 1

Interventions

Rituximab 4blinatumomab 3Whole-Body Irradiation 3Cyclophosphamide 3fludarabine phosphate 2Mycophenolic Acid 2Melphalan 2Lenalidomide 2Clofarabine 2treosulfan 1thymoglobulin 1sabatolimab 1pembrolizumab 1peginterferon alfa-2a 1obinutuzumab 1midostaurin 1ixazomib 1fludarabine 1eribulin 1daratumumab 1acalabrutinib 1Trastuzumab 1Tacrolimus 1Sodium Chloride 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Pentostatin 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methotrexate 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasm, Residual × acalabrutinib × Clear all
NCT03863184 2026-04-28

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Weill Medical College of Cornell University

Phase 2 Active not recruiting
37 enrolled 9 charts
Lymphoid

Neoplasm, Residual, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡